{
  "items": "31",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial",
      "url": "https://www.geneonline.com/senti-bio-wins-fda-rmat-designation-for-senti-202-on-50-response-rate-in-leukemia-trial/",
      "time_published": "20251211T060924",
      "authors": [
        "Bernice Lottering"
      ],
      "summary": "Senti Biosciences Inc. (SNTI) received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202, an investigational CAR-NK therapy for relapsed or refractory acute myeloid leukemia (R/R AML). This designation follows promising Phase-1 data demonstrating a 50% overall response rate and a 42% complete remission rate. The announcement led to significant stock volatility, reflecting investor focus on financial sustainability despite the clinical success and regulatory validation.",
      "banner_image": "https://www.geneonline.com/wp-content/uploads/SNTI-Stock-Image.jpeg",
      "source": "GeneOnline",
      "category_within_source": "General",
      "source_domain": "GeneOnline",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.702660"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.636675"
        }
      ],
      "overall_sentiment_score": 0.25858,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.292087",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Senti Biosciences: Understanding the Market Moves",
      "url": "https://stockstotrade.com/news/senti-biosciences-inc-snti-news-2025_12_10/",
      "time_published": "20251210T150837",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Senti Biosciences Inc. (NASDAQ: SNTI) experienced a significant -10.06% stock drop due to investor concerns, despite recent technological innovations and restructuring efforts. The company faces financial challenges, including a revenue decrease and high debt-to-equity ratio, but also presents growth opportunities in the volatile biopharma sector. Its future hinges on potential breakthroughs that could offset current negative financial figures.",
      "banner_image": "https://content.stockstotrade.com/wp-content/uploads/2025/12/volatile-biotech-stock-market-trends-1.png",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.840839"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.710528"
        }
      ],
      "overall_sentiment_score": -0.415553,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.405579",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ",
      "url": "https://stockstotrade.com/quote/SNTI/",
      "time_published": "20251209T230837",
      "authors": [
        "NULL"
      ],
      "summary": "This page provides live quotes and charts for Senti Biosciences Inc. (SNTI) stock, showing its current price and daily performance. It also includes sections for analyst ratings and earnings, though specific data is currently unavailable. The article promotes a \"millionaire formula\" and offers free trade alerts.",
      "banner_image": "NULL",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.941969"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.811238"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.712048"
        }
      ],
      "overall_sentiment_score": -0.600872,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.648573",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "\u201cSmart\u201d NK Cells: Senti Bio\u2019s Logic-Gated Immunotherapy Strikes R/R AML",
      "url": "https://www.insideprecisionmedicine.com/topics/oncology/smart-nk-cells-senti-bios-logic-gated-immunotherapy-strikes-r-r-aml/",
      "time_published": "20251209T172032",
      "authors": [
        "Jonathan D. Grinstein",
        "PhD"
      ],
      "summary": "Senti Biosciences has developed a \"smart\" CAR NK cell therapy, SENTI-202, demonstrating promising Phase I clinical data for relapsed/refractory AML (R/R AML). This logic-gated immunotherapy utilizes AND/NOT gates to selectively target cancer cells while sparing healthy tissue, achieving durable remissions and eliminating leukemic stem cells without severe toxicities. The technology aims to overcome limitations of traditional CAR T therapies by enabling precise decision-making within therapeutic cells, with potential expansion to solid tumors.",
      "banner_image": "https://www.insideprecisionmedicine.com/wp-content/uploads/2025/12/GettyImages-2196576063-696x387.jpg",
      "source": "Inside Precision Medicine",
      "category_within_source": "General",
      "source_domain": "Inside Precision Medicine",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.226851,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.628399",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.635381",
          "ticker_sentiment_score": "0.103277",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.648175",
          "ticker_sentiment_score": "0.127105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.613928",
          "ticker_sentiment_score": "0.147186",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.645034",
          "ticker_sentiment_score": "0.146556",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy?",
      "url": "https://stockstotrade.com/news/senti-biosciences-inc-snti-news-2025_12_09/",
      "time_published": "20251209T150932",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Senti Biosciences Inc. (NASDAQ: SNTI) has seen an 8.87% stock increase following announcements of scientific advancements, particularly in its SENTI-202 trials for relapsed AML. Leerink initiated coverage with an \"Outperform\" rating and a $6 target, based on Senti Bio's innovative LogicGated gene circuits platform. Despite promising developments, the company faces financial challenges, reporting wider losses in Q3 2025.",
      "banner_image": "https://content.stockstotrade.com/wp-content/uploads/2025/12/biotech-stock-market-innovation-3.png",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908710"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.927499"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.846513"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749975"
        },
        {
          "topic": "technology",
          "relevance_score": "0.621182"
        }
      ],
      "overall_sentiment_score": 0.288787,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.287228",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Senti Biosciences (Nasdaq: SNTI) data show 42% CR/CRh, 7.6-mo remissions in AML",
      "url": "https://www.stocktitan.net/news/SNTI/senti-bio-announces-updated-senti-202-clinical-data-from-ongoing-fmqmjo9sapxv.html",
      "time_published": "20251209T120932",
      "authors": [
        "NULL"
      ],
      "summary": "Senti Biosciences announced updated Phase 1 clinical data for SENTI-202 in relapsed/refractory Acute Myeloid Leukemia patients, demonstrating a 50% Overall Response Rate and 42% Complete Remission/CR with Partial Hematologic Recovery. The therapy also showed 100% MRD negativity in CRs, median remission duration of 7.6 months, and a favorable safety profile, leading to FDA Regenerative Medicine Advanced Therapy (RMAT) designation. Despite the positive clinical results, the stock experienced a significant negative market reaction, dropping 16.11%.",
      "banner_image": "https://ml.globenewswire.com/media/NjFhYmRlNzktNjUwNS00MDFmLThhZmUtNDQ3ZDBkZjJmMTMzLTEyMjE0NDAtMjAyNS0xMi0wOS1lbg==/tiny/Senti-Biosciences-Inc-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.815907"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.731523"
        }
      ],
      "overall_sentiment_score": -0.395778,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.394128",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Senti Biosciences, Inc. Announces Initial Clinical Data for SENTI-202",
      "url": "https://www.tradingview.com/news/tradingview:fe753d18c5089:0-senti-biosciences-inc-announces-initial-clinical-data-for-senti-202/",
      "time_published": "20251209T120932",
      "authors": [],
      "summary": "Senti Biosciences, Inc. announced promising initial clinical data from a Phase 1 trial of SENTI-202 for relapsed/refractory AML, with a 50% ORR and 42% CR/CRh rates observed. The SENTI-202 received FDA RMAT designation, indicating potential for durable remissions and safety. The company plans to expand into pivotal studies and other indications in 2026.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.901263"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.624020"
        }
      ],
      "overall_sentiment_score": 0.890402,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.884325",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile",
      "url": "https://finance.yahoo.com/news/senti-bio-announces-updated-senti-120000090.html",
      "time_published": "20251209T120932",
      "authors": [
        "NULL"
      ],
      "summary": "Senti Biosciences has released updated clinical data from its Phase 1 trial of SENTI-202 in relapsed or refractory Acute Myeloid Leukemia (R/R AML) patients, highlighting deep, MRD-negative, durable complete remissions and a favorable safety profile. The study, presented at ASH 2025, showed a 50% Overall Response Rate and a 42% Complete Remission/CRh rate at the Recommended Phase 2 Dose, with supporting pharmacodynamic data validating the therapy's selective killing mechanism. The FDA has also granted SENTI-202 Regenerative Medicine Advanced Therapy (RMAT) designation, accelerating its potential advancement into pivotal studies.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/ZzRllEwmBJRmtO.L0Gf1ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.499596,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.463645",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Senti Bio (Nasdaq: SNTI) gains FDA RMAT for SENTI-202 after 50% ORR in AML trial",
      "url": "https://www.stocktitan.net/news/SNTI/senti-bio-receives-fda-regenerative-medicine-advanced-therapy-rmat-l42l57mmx5m0.html",
      "time_published": "20251209T070000",
      "authors": [
        "NULL"
      ],
      "summary": "Senti Bio (Nasdaq: SNTI) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202 in adults with relapsed or refractory acute myeloid leukemia (R/R AML) on December 9, 2025. This designation follows an Orphan Drug designation in June 2025 and is supported by Phase 1 data presented at ASH showing a 50% Overall Response Rate (ORR) and 42% Complete Remission (CR/CRh) at the Recommended Phase 2 Dose (RP2D), with a 7.6-month median duration of composite complete remission. Despite this positive news, SNTI\u2019s stock declined 35.56% on the day this news was published, reflecting a significant negative market reaction likely due to underlying balance sheet concerns highlighted in a recent Q3 2025 report.",
      "banner_image": "https://ml.globenewswire.com/media/ZDNjNjljNDUtMWMxZS00ZDcxLWJiZWYtOWI3Y2E2YmM5ZTMzLTEyMjE0NDAtMjAyNS0xMi0wOS1lbg==/tiny/Senti-Biosciences-Inc-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.940823"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.714028"
        }
      ],
      "overall_sentiment_score": 0.123625,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.985924",
          "ticker_sentiment_score": "0.123770",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting",
      "url": "https://www.quiverquant.com/news/Senti+Biosciences%2C+Inc.+to+Host+Conference+Call+on+Updated+Clinical+Results+for+SENTI-202+Prior+to+ASH+Annual+Meeting",
      "time_published": "20251204T135100",
      "authors": [
        "NULL"
      ],
      "summary": "Senti Biosciences, Inc. will host a conference call and webcast on December 9, 2025, to discuss updated clinical results for its SENTI-202 therapy, which is a next-generation CAR-NK cell therapy targeting hematologic malignancies like AML and MDS. The therapy employs a novel Gene Circuit approach to selectively eliminate cancer cells while sparing healthy ones. The company is currently enrolling patients in a Phase 1 trial for this allogeneic treatment.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.811036"
        }
      ],
      "overall_sentiment_score": 0.311316,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.318044",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation",
      "url": "https://www.nasdaq.com/articles/leerink-partners-initiates-coverage-senti-biosciences-snti-outperform-recommendation",
      "time_published": "20251124T045210",
      "authors": [
        "George Maybach"
      ],
      "summary": "Leerink Partners has initiated coverage of Senti Biosciences (SNTI) with an Outperform recommendation. Analysts predict a significant upside of 632.60% from its current price, with an average one-year price target of $13.26/share. Institutional ownership data shows an increase in the number of funds holding SNTI, although total shares owned by institutions decreased slightly over the last quarter.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908586"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.839160"
        }
      ],
      "overall_sentiment_score": 0.445361,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.443978",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Senti Biosciences Loses Cash But Keeps Analyst Support",
      "url": "https://finimize.com/content/senti-biosciences-loses-cash-but-keeps-analyst-support",
      "time_published": "20251117T045210",
      "authors": [
        "Finimize Newsroom"
      ],
      "summary": "Senti Biosciences (SNTI) experienced significant cash burn and a net loss of $18.1 million in Q3, with reserves dropping to $12.2 million from $48.3 million at year-end. Despite dwindling liquidity and high R&D expenses, all three analysts covering the biotech firm maintain 'buy' ratings and a median price target of $12.00, significantly above its current $1.89 share price, reflecting confidence in its research pipeline and potential for breakthroughs. This scenario highlights the high-risk, high-reward nature of biotech investments, where optimism often outweighs immediate financial struggles due to the promise of innovation.",
      "banner_image": "https://finimize.com/_next/image?url=https%3A%2F%2Ffinimize-img.imgix.net%2Fhttps%253A%252F%252Fchivas-assets.s3-eu-west-1.amazonaws.com%252Fstatic%252Fimages%252Ftag_reuters_com_2025_newsml_L1N3WP1AY_1205370442.jpeg%3Fixlib%3Dpython-3.1.2%26s%3D723f8b2812a34e9933aff32c9f4b3a48&w=3840&q=75",
      "source": "Finimize",
      "category_within_source": "General",
      "source_domain": "Finimize",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.915114"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.837521"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.741238"
        }
      ],
      "overall_sentiment_score": 0.136571,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.137170",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Biosciences Faces Losses But Analysts Stay Positive",
      "url": "https://finimize.com/content/senti-biosciences-faces-losses-but-analysts-stay-positive",
      "time_published": "20251117T045210",
      "authors": [],
      "summary": "Despite deepening quarterly losses of $18.1 million and dwindling cash reserves of $12.2 million, Wall Street analysts maintain a bullish stance on Senti Biosciences (SNTI). All major ratings are set to \"buy,\" with a median 12-month price target of $12, significantly above its current trading price. This confidence highlights the market's continued conviction in the long-term potential of biotech R&D, even amid significant cash burn and operational losses.",
      "banner_image": "https://finimize.com/_next/image?url=https%3A%2F%2Ffinimize-img.imgix.net%2Fhttps%253A%252F%252Fchivas-assets.s3-eu-west-1.amazonaws.com%252Fstatic%252Fimages%252Ftag_reuters_com_2025_newsml_L1N3WP1AY_1205370442.jpeg%3Fixlib%3Dpython-3.1.2%26s%3D723f8b2812a34e9933aff32c9f4b3a48&w=3840&q=75",
      "source": "Finimize",
      "category_within_source": "General",
      "source_domain": "Finimize",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.914890"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.830500"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.725818"
        },
        {
          "topic": "finance",
          "relevance_score": "0.649764"
        }
      ],
      "overall_sentiment_score": 0.31937,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.326692",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Senti Bio to present updated clinical data on SENTI-202 at ASH meeting",
      "url": "https://www.investing.com/news/company-news/senti-bio-to-present-updated-clinical-data-on-senti202-at-ash-meeting-93CH-4357085",
      "time_published": "20251113T163800",
      "authors": [
        "Investing.com"
      ],
      "summary": "Senti Biosciences (NASDAQ:SNTI) will present updated clinical data for its lead cancer therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting in December. The company will showcase expanded data from its Phase 1 study in relapsed/refractory acute myeloid leukemia (AML) patients, highlighting continued efficacy, safety, and durability. Senti Bio also reported cash and cash equivalents of $12.2 million as of September 30, 2025, and a net loss of $18.1 million for the third quarter.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904504"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.828756"
        }
      ],
      "overall_sentiment_score": 0.215777,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.300358",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.600585",
          "ticker_sentiment_score": "0.113846",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Brokers Offer Predictions for SNTI Q3 Earnings",
      "url": "https://www.defenseworld.net/2025/10/17/brokers-offer-predictions-for-snti-q3-earnings.html",
      "time_published": "20251017T153718",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "This article reports on brokers' predictions for Senti Biosciences' Q3 earnings, though specific forecasts are not detailed. It highlights recent institutional investment activities in Senti Biosciences, including increased stakes by major hedge funds. The company's profile as a preclinical biotechnology firm developing gene circuit platform technologies for cell and gene therapies is also outlined.",
      "banner_image": "https://www.marketbeat.com/logos/senti-biosciences-inc-logo-1200x675.png?v=20220921072413",
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.940044"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.828844"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.626640"
        }
      ],
      "overall_sentiment_score": 0.010249,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.311657",
          "ticker_sentiment_score": "0.043271",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference - The Manila Times",
      "url": "https://www.manilatimes.net/2025/10/16/tmt-newswire/globenewswire/senti-bio-to-present-at-chardans-9th-annual-genetic-medicines-conference/2202418",
      "time_published": "20251016T131420",
      "authors": [],
      "summary": "Senti Bio (Nasdaq: SNTI) announced it will participate in Chardan's 9th Annual Genetic Medicines Conference on October 2, 2024. Philip Lee, CEO of Senti Bio, is scheduled to present at 4:30 PM ET. A live webcast of the presentation will be available on the company's website.",
      "banner_image": null,
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943386"
        }
      ],
      "overall_sentiment_score": 0.043603,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.313917",
          "ticker_sentiment_score": "0.028859",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Biosciences CEO Timothy Lu to Present at Chardan's 9th Annual Genetic Medicines Conference - Quiver Quantitative",
      "url": "https://www.quiverquant.com/news/Senti+Biosciences+CEO+Timothy+Lu+to+Present+at+Chardan%27s+9th+Annual+Genetic+Medicines+Conference",
      "time_published": "20251016T131300",
      "authors": [],
      "summary": "Senti Biosciences' CEO Timothy Lu will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, to discuss the company's advancements in cell and gene therapies using its proprietary Gene Circuit platform. Management will also hold one-on-one meetings with investors. The presentation will be webcast live on Senti Bio's website, highlighting their focus on developing enhanced therapies for cancer and other diseases.",
      "banner_image": "https://www.quiverquant.com/images/snti_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.020304,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.315881",
          "ticker_sentiment_score": "0.011193",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference - Stock Titan",
      "url": "https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-chardan-s-9th-annual-genetic-medicines-1lwbsdqrxpxk.html",
      "time_published": "20251016T130500",
      "authors": [],
      "summary": "Senti Biosciences (Nasdaq: SNTI) announced that CEO and co-founder Timothy Lu, MD, PhD, will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. A live webcast of the presentation will be available on the company\u2019s Investors > Events page, and management will also be available for one-on-one investor meetings. The company is a clinical-stage biotechnology firm focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949910"
        },
        {
          "topic": "finance",
          "relevance_score": "0.739788"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.538903"
        }
      ],
      "overall_sentiment_score": 0.010078,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.301190",
          "ticker_sentiment_score": "0.031959",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Biosciences (NASDAQ:SNTI) Now Covered by Analysts at HC Wainwright - Defense World",
      "url": "https://www.defenseworld.net/2025/10/15/senti-biosciences-nasdaqsnti-now-covered-by-analysts-at-hc-wainwright.html",
      "time_published": "20251015T065154",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "Senti Biosciences (NASDAQ:SNTI) has recently been covered by analysts at HC Wainwright. This follows previous coverage by Chardan Capital, which maintained a \"buy\" rating with a $12.00 price target. The article also details recent institutional investor activity in SNTI stock and provides a company profile.",
      "banner_image": null,
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921507"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.733479"
        }
      ],
      "overall_sentiment_score": 0.033407,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.323786",
          "ticker_sentiment_score": "0.014893",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes - TradingView",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_L3N3VV0MP:0-h-c-wainwright-initiates-senti-biosciences-with-buy-on-cell-therapy-hopes/",
      "time_published": "20251014T130701",
      "authors": [
        "Refinitiv"
      ],
      "summary": "H.C. Wainwright has initiated coverage of Senti Biosciences (SNTI) with a \"Buy\" rating and a price target of $12, citing the company's promising cell therapy for tough-to-treat blood cancer. The brokerage believes Senti's therapy platform has the potential to treat multiple cancer types, including hematologic malignancies and solid tumors. SNTI shares rose 1.1% in premarket trading following the news.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.802763"
        }
      ],
      "overall_sentiment_score": 0.004818,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.329200",
          "ticker_sentiment_score": "0.010976",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HC Wainwright Initiates Coverage on Senti Biosciences With Buy Rating, $12 Price Target - MarketScreener",
      "url": "https://www.marketscreener.com/news/hc-wainwright-initiates-coverage-on-senti-biosciences-with-buy-rating-12-price-target-ce7d5ad9df8df12d",
      "time_published": "20251014T113151",
      "authors": [
        "MT Newswires"
      ],
      "summary": "HC Wainwright has initiated coverage on Senti Biosciences with a Buy rating and a $12 price target. This announcement comes as Senti Biosciences continues clinical development of its cell and gene therapies, particularly SENTI-202 for hematologic malignancies. The company's stock, trading at $1.730, has seen a 5-day change of +2.98% and a year-to-date change of -52.14%.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.915470"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.841639"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.732000"
        }
      ],
      "overall_sentiment_score": 0.003393,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.305412",
          "ticker_sentiment_score": "0.041496",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Biosciences stock rating initiated at Buy by H.C. Wainwright - Investing.com",
      "url": "https://www.investing.com/news/analyst-ratings/senti-biosciences-stock-rating-initiated-at-buy-by-hc-wainwright-93CH-4285463",
      "time_published": "20251014T110822",
      "authors": [],
      "summary": "H.C. Wainwright has initiated coverage on Senti Biosciences with a Buy rating. This indicates a positive outlook from the analyst firm regarding the company's stock performance. The article title provides this key piece of information.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.842674"
        }
      ],
      "overall_sentiment_score": 0.02616,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.301689",
          "ticker_sentiment_score": "0.042244",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia",
      "url": "https://www.stocktitan.net/news/SNTI/senti-bio-announces-fda-clearance-of-ind-application-for-senti-202-vjuirvgvpxw9.html",
      "time_published": "20231222T063000",
      "authors": [],
      "summary": "Senti Biosciences (Nasdaq: SNTI) announced FDA clearance of its Investigational New Drug (IND) application for SENTI-202, a CAR-NK cell therapy for relapsed or refractory hematologic malignancies including acute myeloid leukemia. The company plans to initiate a Phase 1 clinical trial in Q2 2024, with initial clinical efficacy data expected by year-end 2024 and durability data in 2025. SENTI-202 utilizes Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910842"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.622474"
        }
      ],
      "overall_sentiment_score": 0.022683,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.340209",
          "ticker_sentiment_score": "0.005244",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Gene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facility",
      "url": "https://www.bizjournals.com/sanfrancisco/news/2023/10/09/senti-genefab-alameda.html",
      "time_published": "20231009T154113",
      "authors": [
        "Sarah Klearman"
      ],
      "summary": "GeneFab, a new startup focused on cell and gene therapies, has acquired Senti Biosciences' 92,000-square-foot manufacturing facility in Alameda for $38 million. The company plans to use the facility for its own products and potentially beyond. This move signifies a significant expansion for GeneFab in the biotech manufacturing sector.",
      "banner_image": null,
      "source": "The Business Journals",
      "category_within_source": "General",
      "source_domain": "The Business Journals",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.808132"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.947981"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.719728"
        },
        {
          "topic": "real_estate",
          "relevance_score": "0.739724"
        }
      ],
      "overall_sentiment_score": -0.247321,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.929714",
          "ticker_sentiment_score": "-0.248565",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "GeneFab to Sublease Senti Biosciences cGMP Facility",
      "url": "https://www.contractpharma.com/breaking-news/genefab-to-sublease-senti-biosciences-cgmp-facility/",
      "time_published": "20230814T154113",
      "authors": [
        "Anthony Vecchione"
      ],
      "summary": "GeneFab LLC has entered into a transaction with Senti Biosciences, Inc., to sublease Senti Bio\u2019s cGMP facility and acquire its chemistry, manufacturing, and controls (CMC) capabilities for approximately $38 million. Philip Lee, co-founder and chief technology officer of Senti Bio, will become CEO of GeneFab. This move aims to accelerate the design, development, and manufacturing of innovative genetic medicines.",
      "banner_image": null,
      "source": "Contract Pharma",
      "category_within_source": "General",
      "source_domain": "Contract Pharma",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.938118"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.825045"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.724015"
        }
      ],
      "overall_sentiment_score": 0.238454,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.318619",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.570988",
          "ticker_sentiment_score": "0.107690",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "GeneFab debuts as manufacturer, acquires Senti Bio's production tech for $38M",
      "url": "https://www.fiercepharma.com/manufacturing/genefab-debuts-manufacturer-acquires-senti-bio-production-tech-38m",
      "time_published": "20230814T134900",
      "authors": [
        "Joseph Keenan"
      ],
      "summary": "GeneFab, a new contract research, development, and manufacturing organization for cell and gene therapies, has acquired Senti Biosciences' production technology for up to $38 million. GeneFab will operate out of Senti Bio's 92,000-square-foot facility in Alameda, California, and Senti Bio's co-founder and CTO, Philip Lee, will become GeneFab's chief executive. The facility will employ about 50 workers and support Senti Bio's chimeric antigen receptor natural killer cell pipeline through a service contract.",
      "banner_image": null,
      "source": "Fierce Pharma",
      "category_within_source": "General",
      "source_domain": "Fierce Pharma",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.917830"
        },
        {
          "topic": "finance",
          "relevance_score": "0.645182"
        }
      ],
      "overall_sentiment_score": -0.640969,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.966565",
          "ticker_sentiment_score": "-0.637501",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "GeneFab Launches to Offer Innovative Manufacturing and",
      "url": "https://www.globenewswire.com/news-release/2023/08/10/2722694/0/en/GeneFab-Launches-to-Offer-Innovative-Manufacturing-and-Synthetic-Biology-Design-Services-for-a-Broad-Range-of-Genetic-Medicines.html",
      "time_published": "20230810T083500",
      "authors": [],
      "summary": "GeneFab, LLC has launched, backed by Celadon Partners, and will offer innovative manufacturing and synthetic biology design services for genetic medicines. The company acquired Senti Bio's CMC capabilities and subleased its cGMP facility for approximately $38 million, with Philip Lee, PhD, transitioning from Senti Bio to become GeneFab's CEO. GeneFab aims to accelerate the design, development, and manufacturing of genetic medicines, including supporting Senti Bio's clinical manufacturing of CAR-NK cells through a service contract.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947991"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.722666"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.645749"
        }
      ],
      "overall_sentiment_score": -0.200072,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.220360",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Alameda Welcomes Senti Bio Manufacturing",
      "url": "https://alamedapost.com/news/alameda-welcomes-senti-bio-manufacturing/",
      "time_published": "20230703T074200",
      "authors": [
        "Adam Gillitt"
      ],
      "summary": "Senti Bio, a medical technology company, celebrated the opening of its new manufacturing plant on Bay Farm Island, Alameda, on June 28. This facility will produce Senti-202, an innovative cell therapy designed to treat acute myeloid leukemia, a severe form of blood cancer. The company aims to advance its programs and obtain FDA approval for clinical trials later this year.",
      "banner_image": null,
      "source": "Alameda Post",
      "category_within_source": "General",
      "source_domain": "Alameda Post",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920548"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.901614"
        }
      ],
      "overall_sentiment_score": 0.40701,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.444559",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SNTI Stock Price and Chart \u2014 NASDAQ:SNTI",
      "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/",
      "time_published": "20220929T183704",
      "authors": [],
      "summary": "This article provides a detailed overview of Senti Biosciences, Inc. (NASDAQ: SNTI) stock, including its current price, historical performance, key financial metrics, and analyst forecasts. It covers information such as market capitalization, revenue, earnings, employee count, and the company's business description. The article also includes frequently asked questions regarding SNTI's stock performance and financial data.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.946489"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.913061"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.832844"
        }
      ],
      "overall_sentiment_score": 0.222395,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.202641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Senti Biosciences (NASDAQ:SNTI) investors are sitting on a loss of 79% if they invested a year ago",
      "url": "https://www.nasdaq.com/articles/senti-biosciences-nasdaq:snti-investors-are-sitting-on-a-loss-of-79-if-they-invested-a",
      "time_published": "20220912T082200",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Senti Biosciences (NASDAQ:SNTI) investors have experienced a significant loss of 79% over the past year. Despite a strong 191% revenue increase in the last twelve months, the stock has plummeted, suggesting a disconnect between revenue growth and market perception, potentially due to unusual circumstances or investor overreaction. The article advises a closer look at the company's fundamentals before considering a purchase.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906978"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.818256"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.746410"
        }
      ],
      "overall_sentiment_score": -0.64517,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.645434",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Kriya Appoints Curt Herberts as President and Chief Operating Officer",
      "url": "https://www.businesswire.com/news/home/20220825005223/en/Kriya-Appoints-Curt-Herberts-as-President-and-Chief-Operating-Officer",
      "time_published": "20220825T183704",
      "authors": [],
      "summary": "Kriya Therapeutics, a gene therapy company, has appointed Curt Herberts, M.B.S., as President and Chief Operating Officer. Herberts will oversee all general and administrative functions and brings extensive experience from his previous roles at Senti Biosciences and Sangamo Therapeutics. His appointment is expected to help Kriya expand its operations and capabilities in developing gene therapies.",
      "banner_image": "https://www.businesswire.com/images/default_thumbnail_1.gif",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926333"
        },
        {
          "topic": "finance",
          "relevance_score": "0.719599"
        }
      ],
      "overall_sentiment_score": -0.235889,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "SNTI",
          "relevance_score": "0.940727",
          "ticker_sentiment_score": "-0.233604",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    }
  ]
}